From June 16 to 18, 2026, the 24th World Pharmaceutical Congress China (CPHI China 2026) was grandly held at the Shanghai New International Expo Center. As a professional service provider specializing in regulatory consulting and import registration for pharmaceuticals and health products, our company actively participated in this event, aiming to offer overseas pharmaceutical enterprises planning to enter the Chinese market precise and efficient regulatory access solutions.
Regarding core business areas such as import drug and health supplement registration agency services, clinical trial applications, post-market management of drug changes, re-registration of domestic and imported drugs, and compliance with Chinese Pharmacopoeia, our experienced regulatory expert team conducted in-depth one-on-one communication with clients. Based on the current status of drug research and registration in different countries and regions, we provided forward-looking and practical regulatory strategy suggestions in accordance with Chinese regulations.
